Filippa Stenberg
Direttore/Membro del Consiglio presso SWEDISH ORPHAN BIOVITRUM AB
Patrimonio netto: 13 599 $ in data 30/04/2024
Posizioni attive di Filippa Stenberg
Società | Posizione | Inizio | Fine |
---|---|---|---|
SWEDISH ORPHAN BIOVITRUM AB | Direttore/Membro del Consiglio | - | - |
Independent Dir/Board Member | - | - | |
INVESTOR AB | Corporate Officer/Principal | - | - |
Investor AB (Investment Company)
Investor AB (Investment Company) Financial ConglomeratesFinance Investor AB (Investment Company) (Investor-IC) is the investment division of Investor AB (STO: INVE-B; LSE: INU), a Swedish public company established in 1916 as the investment vehicle for the Wallenberg family, which still owns a significant part of the firm. Investor AB is an industrial holding company which manages private equity funds listed on the Swedish stock exchange. Headquartered in Stockholm, Investor-IC is a socially responsible investor which supports the OECD Guidelines for Multinational Enterprises, including anti-corruption and human rights. They are committed to the development of society at large and sponsor youth, education and entrepreneurship activities. | Gestore di Portafoglio-Azioni | 01/01/2017 | - |
Analyst-Equity | 01/01/2012 | 01/12/2013 |
Storia della carriera di Filippa Stenberg
Precedenti posizioni note di Filippa Stenberg
Società | Posizione | Inizio | Fine |
---|---|---|---|
Atlas Antibodies AB
Atlas Antibodies AB BiotechnologyHealth Technology Atlas Antibodies AB develops antibodies and reagents for Mass Spectrometry (MS)-based quantitative proteomics. Its project Human Protein Atlas aim to present an expression map of the complete human proteome. It offers characterized antibodies to various protein coding human genes; Triple A Polyclonals that are research grade rabbit polyclonal antibodies; and mouse monoclonal antibodies to selected proteins, as a complement to rabbit polyclonal antibodies. Its antibodies are used to study human proteins, for basic research purposes and clinical research in various disease areas, such as cancer and neurological brain diseases. The company was founded by Jan Fredrik Pontén, Karin Marianne Hansson, Henrik Wernérus, and Carl Erik Mathias Uhlén in 2006 and is headquartered in Stockholm, Sweden. | Corporate Officer/Principal | - | - |
Swedbank AB (Broker) | Vendite & Marketing | 22/08/2011 | - |
Formazione di Filippa Stenberg
Stockholm School of Economics | Graduate Degree |
Statistiche
Distribuzione geografica
Svezia | 7 |
Posizioni
Corporate Officer/Principal | 2 |
Sales & Marketing | 1 |
Analyst-Equity | 1 |
Settori
Finance | 4 |
Health Technology | 3 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 2 |
---|---|
SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
INVESTOR AB | Finance |
Aziende private | 3 |
---|---|
Swedbank AB (Broker) | Finance |
Investor AB (Investment Company)
Investor AB (Investment Company) Financial ConglomeratesFinance Investor AB (Investment Company) (Investor-IC) is the investment division of Investor AB (STO: INVE-B; LSE: INU), a Swedish public company established in 1916 as the investment vehicle for the Wallenberg family, which still owns a significant part of the firm. Investor AB is an industrial holding company which manages private equity funds listed on the Swedish stock exchange. Headquartered in Stockholm, Investor-IC is a socially responsible investor which supports the OECD Guidelines for Multinational Enterprises, including anti-corruption and human rights. They are committed to the development of society at large and sponsor youth, education and entrepreneurship activities. | Finance |
Atlas Antibodies AB
Atlas Antibodies AB BiotechnologyHealth Technology Atlas Antibodies AB develops antibodies and reagents for Mass Spectrometry (MS)-based quantitative proteomics. Its project Human Protein Atlas aim to present an expression map of the complete human proteome. It offers characterized antibodies to various protein coding human genes; Triple A Polyclonals that are research grade rabbit polyclonal antibodies; and mouse monoclonal antibodies to selected proteins, as a complement to rabbit polyclonal antibodies. Its antibodies are used to study human proteins, for basic research purposes and clinical research in various disease areas, such as cancer and neurological brain diseases. The company was founded by Jan Fredrik Pontén, Karin Marianne Hansson, Henrik Wernérus, and Carl Erik Mathias Uhlén in 2006 and is headquartered in Stockholm, Sweden. | Health Technology |
- Borsa valori
- Insiders
- Filippa Stenberg
- Esperienza